|A-54556A natural acyldepsipeptide (ADEP) antibiotic|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Cas No.||95398-45-1||SDF||Download SDF|
|Synonyms||ADEP 1,A-54556 Factor A|
|Chemical Name||(4R)-(6→2)-lactone N-[(2E,4E,6E)-1-oxo-2,4,6-octatrien-1-yl]-L-phenylalanyl-L-seryl-L-prolyl-N-methyl-L-alanyl-L-alanyl-4-methyl-L-proline|
|Canonical SMILES||O=C([[email protected]@H](NC(/C=C/C=C/C=C/C)=O)CC1=CC=CC=C1)N[[email protected]@H](COC2=O)C(N3[[email protected]](C(N([[email protected]@H](C)C(N[[email protected]](C(N4[[email protected]]2C[[email protected]@H](C)C4)=O)C)=O)C)=O)CCC3)=O|
|Solubility||Soluble in DMSO||Storage||Store at -20°C|
|Shipping Condition||Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
IC50: 0.2 μg/ml for Bacillus subtilis 168
A-54556A is a natural acyldepsipeptide (ADEP) antibiotic.
Acyldepsipeptides (ADEP), a new class of antibiotics, has antibacterial activity against Gram-positive bacteria. The acyldepsipeptides are active against isolates that are resistant to antibiotics, implying a new target identify as ClpP.
In vitro: Previous study found that the treatment of B. subtilis with 1.6 mg/ml of A-54556A reduced the number of viable cells by 2 log units. In addition, the biosynthesis of DNA, RNA, protein, cell wall and fatty acid proceeded unhindered for 1 h at 2 mg/ml A-54556A, whereas classical antibiotics were clearly distinguished by preferential inhibition of their target pathway. Microscopic examination showed that after addition of A-54556A at concentrations as low as 0.4 mg/ml, B. subtilis started to form filaments .
In vivo: Two A-54556A analogs, ADEP 2 and ADEP 4, were proven to be active in the treatment of bacterial infections in rodents. When mice were challenged with a lethal systemic infection of E. faecalis, 1 mg/kg ADEP 2 or 0.5 mg/kg ADEP 4 were sufficient for 100% survival. In lethal sepsis caused by S. aureus, 12.5 mg/kg ADEP 4 rescued 80% of the mice and reduced the bacterial loads in liver, spleen and lung by 2–3 log units compared to an untreated control .
Clinical trial: Up to now, A-54556A is still in the preclinical development stage.
 H. Brtz-Oesterhelt, D. Beyer, H. P. Kroll, et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nature Medicine 11(10), 1082-1087 (2005).